clinical trial · NCT06605404
Pan-tumor MRD Study
Paradigm Health·—·recruiting·n = 1,350
Muscle Invasive Bladder Urothelial CarcinomaEsophageal CancerGastric and Gastroesophageal Junction (GEJ) AdenocarcinomaMelanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)Pancreatic (Exocrine Only)Mix of Solid Tumors (MOST)blood and tissue samplesblood and tissue samples
brief summary
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
started
Jan 8, 2025
primary completion
Dec 1, 2031
completion
Apr 1, 2032
last updated
Aug 14, 2025
official title
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol